Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;15(4):551-561.
doi: 10.1007/s11684-020-0760-2. Epub 2021 Apr 24.

Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution

Zhaoshi Bao  1   2   3 , Yongzhi Wang  1   2 , Qiangwei Wang  1 , Shengyu Fang  1 , Xia Shan  1   4 , Jiguang Wang  5 , Tao Jiang  6   7   8   9
Affiliations
Review

Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution

Zhaoshi Bao et al. Front Med. 2021 Aug.

Abstract

Glioma is the most common lethal tumor of the human brain. The median survival of patients with primary World Health Organization grade IV glioma is only 14.6 months. The World Health Organization classification of tumors of the central nervous system categorized gliomas into lower-grade gliomas and glioblastomas. Unlike primary glioblastoma that usually develop de novo in the elderly, secondary glioblastoma enriched with an isocitrate dehydrogenase mutant typically progresses from lower-grade glioma within 5-10 years from the time of diagnosis. Based on various evolutional trajectories brought on by clonal and subclonal alterations, the evolution patterns of glioma vary according to different theories. Some important features distinguish the normal brain from other tissues, e.g., the composition of the microenvironment around the tumor cells, the presence of the blood-brain barrier, and others. The underlying mechanism of glioma recurrence and evolution patterns of glioma are different from those of other types of cancer. Several studies correlated tumor recurrence with tumor heterogeneity and the immune microenvironment. However, the detailed reasons for the progression and recurrence of glioma remain controversial. In this review, we introduce the different mechanisms involved in glioma progression, including tumor heterogeneity, the tumor microenvironment and drug resistance, and their pre-clinical implements in clinical trials. This review aimed to provide new insights into further clinical strategies for the treatment of patients with recurrent and secondary glioma.

Keywords: evolution mechanism; glioma; secondary glioma; strategies; tumor heterogeneity.

PubMed Disclaimer

References

    1. Wang Y, Jiang T. Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett 2013; 331(2): 139–146 - PubMed
    1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114(2): 97–109 - PubMed - PMC
    1. Schiff D, van den Bent M, Vogelbaum MA, Wick W, Miller CR, Taphoorn M, Pope W, Brown PD, Platten M, Jalali R, Armstrong T, Wen PY. Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus. Neuro Oncol 2019; 21(7):837–853 - PubMed - PMC
    1. Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 2009; 100(12): 2235–2241 - PubMed
    1. Cavenee WK, Furnari FB, Nagane M. Diffusely infiltrating astrocytomas. In: Kleihues P, Cavenee WK. Pathology and Genetics of Tumors of the Nervous System. WHO Classification of Tumors. Lyon: IARC press, 2000: 10–21

LinkOut - more resources